Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: GlaxoSmithKline plc

Market Cap 7.68TCr 10TCr 8.85TCr 8.16TCr 14TCr 9,57600Cr 14TCr 97TCr 38TCr 4,71900Cr 38TCr 37TCr 16,35700Cr P/E 2026 *
12.3x
P/E 2027 * 11.4x
Enterprise Value 9.18TCr 12TCr 11TCr 9.76TCr 17TCr 11,44800Cr 17TCr 1,16100Cr 45TCr 5,64100Cr 46TCr 45TCr 19,55400Cr EV / Sales 2026 *
2.72x
EV / Sales 2027 * 2.5x
Free-Float
92.29%
Yield 2026 *
3.74%
Yield 2027 * 3.96%
Manager TitleAgeSince
Chief Executive Officer - 01/01/2026
Director of Finance/CFO 64 01/05/2023
Chief Tech/Sci/R&D Officer - 01/12/2021
Director TitleAgeSince
Director/Board Member - 06/05/2026
Director/Board Member 64 01/01/2018
Chairman 68 01/09/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-0.40% - - 10TCr
-1.21%-5.37%+39.94%+145.38% 98TCr
-2.48%-4.17%+51.52%+39.07% 55TCr
-2.14%-3.68%+16.71%+56.15% 38TCr
-2.28%+0.25%+25.86%+16.53% 32TCr
+1.31%-1.13%+26.14%+14.29% 27TCr
+1.13%-2.20%+25.41%+31.43% 27TCr
+5.06%+2.18%-39.91%-45.79% 19TCr
-1.19%-4.65%+16.56%+47.00% 18TCr
-1.35%-1.68%+14.59%+56.94% 15TCr
Average -0.32%-2.68%+19.65%+40.11% 36.6TCr
Weighted average by Cap. -0.85%-3.38%+28.41%+64.21%

Financials

2026 *2027 *
Net sales 3.38TCr 4.47TCr 3.9TCr 3.59TCr 6.32TCr 4,21600Cr 6.37TCr 43TCr 17TCr 2,07800Cr 17TCr 16TCr 7,20100Cr 3.55TCr 4.7TCr 4.09TCr 3.77TCr 6.64TCr 4,42600Cr 6.68TCr 45TCr 17TCr 2,18100Cr 18TCr 17TCr 7,56000Cr
Net income 626.62Cr 829.44Cr 722.69Cr 666.2Cr 1.17TCr 78TCr 1.18TCr 7.93TCr 3.08TCr 39TCr 3.11TCr 3.05TCr 1,33500Cr 666.92Cr 882.78Cr 769.16Cr 709.04Cr 1.25TCr 83TCr 1.26TCr 8.44TCr 3.28TCr 41TCr 3.31TCr 3.24TCr 1,42100Cr
Net Debt 1.5TCr 1.99TCr 1.73TCr 1.59TCr 2.81TCr 1,87100Cr 2.83TCr 19TCr 7.37TCr 92TCr 7.45TCr 7.29TCr 3,19600Cr 1.19TCr 1.58TCr 1.38TCr 1.27TCr 2.23TCr 1,48900Cr 2.25TCr 15TCr 5.86TCr 73TCr 5.93TCr 5.8TCr 2,54300Cr
Logo GlaxoSmithKline plc
GSK plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (41.3%): intended mainly for HIV infection (57% of net sales), immune system disorders and respiratory diseases (28.3%), and cancer (14.7%); - OTC and parapharmaceutical medicine (30.7%); - vaccines (28%). Net sales are distributed geographically as follows: the United Kingdom (2.1%), Europe (21%), the United States (51.6%), and other (25.3%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
21
Last Close Price
19.23GBP
Average target price
20.77GBP
Spread / Average Target
+7.99%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!